AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T
#MMSM
3 people · 5 posts
Heat trend for this story
Heat now 0·Peak in the comparable set 1 (Apr 21 07:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted1
Heat over time
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.
Records
CAR-PRISM’s universal MRD negativity happened in a window of healthier T cells and lower burden; solid tumors do not have that window yet.
Other cases in this chapter
- autogene cevumeran7 of 8 responders alive at 4–6 years; 2 of 8 non-responders
- EGFRvIII CAR13 patients: 2 PR, 7 SD
- mRNA-4157Melanoma RFS HR 0.44
- 局部 nivolumabOral pre-cancer clinical response 85%, 1-year clearance 82%
Floor
x.com@Score6060
OncLive.com@OncLiveScore6060 Daniel Auclair@AuclairDanScore6060 The CAR-PRISM study is now in published today online in Nature Medicine #AACR26
Daniel Auclair@AuclairDanScore6060
Daniel Auclair@AuclairDanScore6060 Looking forward to the results of the CAR-PRISM trial presented in Hall H this morning